ImmunityBio shared good early results for its CD19 CAR-NK therapy, showing it works for treating Waldenstrom's macroglobulinemia.

Oct 31, 2026, 9:41 PM ETTrialRead the original at fr.tradingview.com

Good for IBRX

ImmunityBio reported that its therapy cleared symptoms in 2 patients, and 1 remained in remission for 6 months. This is an encouraging early sign, though the small group and use of rituximab in that patient limit what it proves.

IBRX · ImmunityBio

AI read · Good for IBRX

The AI's read

This gives ImmunityBio an encouraging early sign for its cancer program, especially because no significant toxic side effects were reported. But only 2 patients were described, and the person still in remission also received rituximab. The report suggests promise, but does not show whether the treatment works on its own.

Get alerts for IBRX

Follow ImmunityBio (IBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IBRX

Free on the App Store and Google Play, or on the web.